Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

67%

2 trials in Phase 3/4

Results Transparency

0%

0 of 1 completed trials have results

Key Signals

1 recruiting

Enrollment Performance

Analytics

Phase 4
2(66.7%)
N/A
1(33.3%)
3Total
Phase 4(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT06723197Phase 4Recruiting

Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication

Role: collaborator

NCT05049902Phase 4Completed

Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication

Role: collaborator

NCT05901779Not ApplicableUnknown

Effect of Probiotic Supplements on Gastric Cancer Patients Receiving Neoadjuvant Chemotherapy

Role: collaborator

All 3 trials loaded